

**Department of Health and Human Services  
Public Health Service  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Surveillance and Epidemiology**

Date: September 3, 2009

To: M. Dianne Murphy, MD  
Director, Office of Pediatric Therapeutics (OPT), OIASI  
Office of the Commissioner

CDR Lisa L. Mathis, USPHS, MD  
Associate Director, Pediatric and Maternal Health Team (PMHS)  
Office of New Drugs

Thru: Laura Governale, Pharm.D., MBA  
Drug Use Data Analyst Team Leader  
Division of Epidemiology  
Office of Surveillance and Epidemiology

From: Hina Mehta, Pharm.D.  
Drug Use Data Analyst  
Division of Epidemiology  
Office of Surveillance and Epidemiology

Subject: Abilify<sup>®</sup> (aripiprazole), Geodon<sup>®</sup> (ziprasidone), Seroquel<sup>®</sup>  
(quetiapine), Zyprexa<sup>®</sup> (olanzapine), Risperdal<sup>®</sup> (risperidone),  
Invega<sup>®</sup> (paliperidone) Drug Use Review

Drug Name(s): Abilify<sup>®</sup> (aripiprazole), Geodon<sup>®</sup> (ziprasidone), Seroquel<sup>®</sup>  
(quetiapine), Zyprexa<sup>®</sup> (olanzapine), Risperdal<sup>®</sup> (risperidone),  
Invega<sup>®</sup> (paliperidone)

Application Type/Number: Various

Applicant/sponsor: Various

OSE RCM #: 2009-1004

**\*\*This document contains proprietary drug use data obtained by FDA under contract. The drug use data/information cannot be released to the public/non-FDA personnel without contractor approval obtained through the FDA/CDER Office of Surveillance and Epidemiology.\*\***

## EXECUTIVE SUMMARY

This review examines drug utilization patterns for six atypical antipsychotics, Abilify<sup>®</sup> (aripiprazole), Geodon<sup>®</sup> (ziprasidone), Seroquel<sup>®</sup> (quetiapine), Zyprexa<sup>®</sup> (olanzapine), Risperdal<sup>®</sup> (risperidone), Invega<sup>®</sup> (paliperidone), in the pediatric population (age 0-2 years, 3-6 years, 7-12 years, 13-17 years, and 18+ years) from year 2004 through June 2009. Since approximately 56%-81% of the atypical antipsychotics were sold to U.S. outpatient retail settings during year 2008, this review focuses on the outpatient setting.

- All of the antipsychotic agents studied except for olanzapine had an increase in the number of dispensed prescriptions over the past 5 years.
- Dispensed prescriptions for aripiprazole increased the most by approximately 135% from year 2004 to year 2008.
- Antipsychotic use among pediatric patients has increased by 22% over the 5 years. The greatest increase was seen for aripiprazole during this time period.
- Risperidone had the most prescriptions dispensed (26%) to pediatric patients (0-17 years) and had a greater amount of use in younger children compared to the other antipsychotics. Aripiprazole had the second highest number of dispensed prescriptions (23%) in the pediatric population.
- In year 2008, 2.3 million unique patients received a prescription for quetiapine followed by risperidone with 1.5 million and aripiprazole with 1.2 million.
- For all of the agents studied, the majority of prescriptions dispensed to patients over the entire study period were prescribed by Psychiatrists.
- In children aged 7-12 years old, concomitant use with stimulant medications were most common for those already on aripiprazole, risperidone and olanzapine. Mood stabilizing agents, other antipsychotics and antidepressants were the most common concomitant products for quetiapine and ziprasidone in this age group as well as for older age groups.

## 1 INTRODUCTION

Using the currently available proprietary drug use databases licensed by the Agency, this review describes outpatient drug use patterns for Abilify<sup>®</sup> (aripiprazole), Geodon<sup>®</sup> (ziprasidone), Seroquel<sup>®</sup> (quetiapine), Zyprexa<sup>®</sup> (olanzapine), Risperdal<sup>®</sup> (risperidone), Invega<sup>®</sup> (paliperidone) in the pediatric population as well as in the adult population for years 2004 through 2008 and year-to-date June 2009.

## 2 METHODS AND MATERIALS

### 2.1 DETERMINING SETTINGS OF CARE

IMS Health, IMS National Sales Perspectives<sup>™</sup> data (*see Appendix 2*) were used to determine the setting in which these six atypical antipsychotic products were sold. Sales of these products by number of bottles, packets of pills (eaches) sold from the manufacturer into the various retail and non-retail channels of distribution were analyzed for year 2008 (*data not provided*).<sup>1</sup> During the review period, retail settings (chain stores, independent pharmacies, and food stores) accounted for the majority of atypical antipsychotic product sales (56% or greater). Distribution towards non-retail pharmacy settings ranged from 22% to 37% during year 2008. The long term care setting within the non-retail channels received the majority of atypical antipsychotic sales. Mail order distribution ranged from 4% to 8% for the six agents analyzed. Thus, we examined outpatient utilization patterns. Mail order and long term care data are not included in this analysis.

---

<sup>1</sup> IMS Health, IMS National Sales Perspectives<sup>™</sup>, Years 2004-2008, Data extracted Aug 2009, Source file: 0908apsy.DVR

## 2.2 DATA SOURCES USED

Outpatient use and patient demographics (stratified by ages 0-2 years, 3-6 years, 7-12 years, 13-17 years, and 18+ years) were measured from SDI Vector One<sup>®</sup>: National (VONA) and Total Patient Tracker (TPT) (*Appendix 2*). Indications for use were obtained from the SDI's Physician's Drug and Diagnosis Audit (PDDA) (*Appendix 2*). From these data sources, estimates of the number of prescriptions dispensed, the number of patients who received a prescription for Abilify<sup>®</sup> (aripiprazole), Geodon<sup>®</sup> (ziprasidone), Seroquel<sup>®</sup> (quetiapine), Zyprexa<sup>®</sup> (olanzapine), Risperdal<sup>®</sup> (risperidone), Invega<sup>®</sup> (paliperidone), and the number of drug mentions by office-based physicians, were obtained for years 2004-2008 and year-to-date June 2009.

## 3 RESULTS

### 3.1 DISPENSED PRESCRIPTIONS

Figure 1 in Appendix 1 shows the total number of prescriptions dispensed in the outpatient retail setting (mail order excluded) for Abilify<sup>®</sup> (aripiprazole), Geodon<sup>®</sup> (ziprasidone), Seroquel<sup>®</sup> (quetiapine), Zyprexa<sup>®</sup> (olanzapine), Risperdal<sup>®</sup> (risperidone), Invega<sup>®</sup> (paliperidone). During year 2008, nearly 32 million prescriptions were dispensed for these products, an increase of 31% from approximately 24.4 million dispensed prescriptions in year 2004. Approximately 11.9 million prescriptions were dispensed for quetiapine (37% of market) followed by risperidone (25% of market) and aripiprazole (16% of market) with 7.9 million and 5.2 million prescriptions, respectively. All of the agents had an increase in the number of prescriptions dispensed in the past 5 years except for olanzapine which decreased by about a third during the same time period. Dispensed prescriptions for aripiprazole increased by 135% from year 2004 (2,217,625 prescriptions) to year 2008 (5,220,606 prescriptions) followed by ziprasidone with 71% increase and quetiapine with 66% increase.

### 3.2 DISPENSED PRESCRIPTION BY PEDIATRIC AGE GROUPS

Antipsychotic use in the pediatric population (0-17 years) has increased 22% in the past 5 years (Figure 2: Appendix 1). The greatest increase was seen for aripiprazole at 96%. In year 2008, of the six agents analyzed, risperidone had the most prescriptions dispensed to pediatric patients aged 0-17 years (26% of all risperidone dispensed to pediatric patients versus adults; 2.1 million risperidone prescriptions), followed by aripiprazole (23%; 1.2 million prescriptions), quetiapine (9%; 1.1 million prescriptions), ziprasidone (10%; 238,425 prescriptions), olanzapine (4%; 169,121 prescriptions), and paliperidone (11%; 74,559 prescriptions). Analysis of pediatric sub-age groups revealed that the majority of antipsychotic use during year 2008 was among those aged 13-17 years; aripiprazole (13%), quetiapine (6%), ziprasidone (7%), olanzapine (2%), and paliperidone (7%). Risperidone, on the other hand, was most commonly dispensed to pediatric patients aged 7-12 years, accounting for 14% of dispensed prescriptions. Prescriptions dispensed to pediatric patients aged 0-2 years and 3-6 years accounted for less than 1% of the combined total dispensed prescriptions for all six agents with the exception of risperidone in which 2% of prescriptions are dispensed to pediatrics aged 3-6 years (Table 1: Appendix 1).

### 3.3 PATIENT-LEVEL DATA

Trends for patient data were similar to that of prescription data. In year 2008, approximately 5.4 million patients received a prescription for these selected antipsychotic agents in the outpatient retail pharmacy setting, an increase of 21% from 4.5 million patients in year 2004. Approximately, 2.3 million unique patients received a prescription for quetiapine followed by risperidone and aripiprazole with 1.5 million and 1.2 million, respectively. As with dispensed prescription data, analysis of pediatric sub-age groups revealed similar trends in use with patient-level data (Table 2: Appendix 1).

### 3.4 DIAGNOSES ASSOCIATED WITH USE

We also examined the most common diagnosis associated with the use of Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega® (paliperidone) as reported by office-based physician practices in the U.S. (Appendix 1: Tables 3a-3e). Diagnoses among the pediatric age groups 0-2 years and 3-6 years were below the acceptable count allowable to provide a reliable estimate. Among the pediatrics aged 7-12 years “Bipolar Affective NOS” ICD-9 296.7 was the most common diagnosis associated with a mention of aripiprazole with approximately 25% of all mentions for that age group from year 2004 through year to date June 2009 followed by “Attention Deficit Dis” ICD-9 314.0 with 17%. For risperidone, the most common diagnosis among pediatrics aged 7-12 years was “Attention Deficit Dis” ICD-9 314-0 with 18% followed by “Bipolar Affective NOS” ICD-9 296.7 and “Infantile Autism” ICD-9 299.0 with 15% and 11%, respectively. For adolescents aged 13-17 years the most common diagnosis associated with a mention for aripiprazole, quetiapine, olanzapine, and ziprasidone was “Bipolar Affective NOS” ICD-9 296.7. “Attention Deficit Dis” ICD-9 314-0 and “Infantile Autism” ICD-9 299.0 were the most common diagnosis for risperidone and paliperidone, respectively, for this age group.

### **3.5 PEDIATRIC DISPENSED PRESCRIPTION BY PRESCRIBING SPECIALTY**

Table 4a-4f in Appendix 1 shows the total number of prescriptions dispensed for Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega® (paliperidone) by patient age and physician specialty. The majority of prescriptions dispensed to patients were prescribed by Psychiatrists over the entire study period for the pediatric as well as adult age groups for all of the agents studied. During year 2008, Nurse Practitioners were the second most common prescriber for aripiprazole, ziprasidone and paliperidone for both adult and pediatric age groups. For risperidone, quetiapine, and olanzapine, GP/FM/DO<sup>2</sup> were the second most common prescribers of these medications to both adult and pediatric age groups.

### **3.6 CONCOMITANT USE**

Tables 5a-5e in Appendix 1 shows the total number of health care physician mentions where one of the select antipsychotics were used concomitantly with another class of products to treat the same diagnosis. Concomitancy for all of the agents among the pediatric age groups 0-2 years and 3-6 years were below the acceptable count allowable to provide a reliable estimate of use. In those aged 7-12 years old, concomitant use with stimulant medications were most common for aripiprazole, risperidone and olanzapine. For quetiapine and ziprasidone, mood stabilizing agents such as anticonvulsants, other antipsychotics, and antidepressants were commonly used together to treat the same diagnosis. In those aged 13-17 years, concomitant use with mood stabilizing agents, other antipsychotics and antidepressants were the most common concomitant class of products for all antipsychotic agents studied.

## **4 LIMITATIONS**

Findings from this consult should be interpreted in the context of the known limitations of the databases used. We estimated Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega® (paliperidone) are distributed primarily in outpatient settings based on the IMS Health, IMS National Sales Perspectives™. These data do not provide a direct estimate of use but do provide a national estimate of units sold from the manufacturer into the various channels of distribution. The amount of product purchased by these retail and non-retail channels of distribution may be a possible surrogate for use, if we assume the facilities purchase drugs in quantities reflective of actual patient use.

SDI's Physician Drug & Diagnosis Audit (PDDA) data provide estimates of patient demographics and indications for use of medicinal products in the U.S. Due to the sampling and data collection methodologies,

---

<sup>2</sup> GP/FM/DO – General Practice, Family Medicine, Doctor of Osteopathy

the small sample size can make these data unstable, particularly if use is not common in the pediatric population. SDI recommends caution interpreting projected annual uses or mentions below 100,000 as the sample size is very small with correspondingly large confidence intervals.

## **5 CONCLUSIONS**


All of the antipsychotic agents studied except for olanzapine had an increase in the number of dispensed prescriptions over the past 5 years. Dispensed prescription for Abilify® (aripiprazole) increased the greatest amount (135%). Antipsychotic use among pediatric patients aged 0-17 years have increased 22% over the past 5 years. Use among pediatrics aged 0-2 years and 3-6 years accounted for less than 1% of the total for each of the antipsychotic agents studied. Risperidone was the most commonly dispensed atypical antipsychotic agent among pediatrics, especially those aged 7-12 years. Aripiprazole pediatric prescriptions are most commonly dispensed to adolescents aged 13-17 years. Trends for patient data were similar to that of prescription data. Psychiatrists prescribe the majority of antipsychotic prescriptions dispensed. In younger children (7-12 years old), concomitant use with stimulant medications were most common for aripiprazole, risperidone and olanzapine. Mood stabilizing agents, other antipsychotics and antidepressants were the most common concomitant class of products used with quetiapine and ziprasidone in this age group as well as for older age groups.

## APPENDICES

### APPENDIX 1: Figures and Tables


---

Figure 1: Total Number of Dispensed Prescriptions for 6 Atypical Antipsychotic Agents Through U.S. Outpatient Retail Pharmacies, Years 2004-2008 and YTD Jun 2009



Source: SDI: Vector One®: National. Data Extracted 8-4-09. File: VONA 2009-1004 TRx 8-4-09.qry

**Figure 2: Total Number of Prescriptions Dispensed for 6 Atypical Antipsychotics Among Pediatrics 0-17 Years Through U.S. Outpatient Retail Pharmacies, 2004-2008 and YTD Jun 2009**



Source: SDI: Vector One: National. Data Extracted 9-1-09. File: VONA 2009-1004 TRx by Ages 0-17 only 9-1-09.qry

Table 1: Total Number of Prescriptions Dispensed for Atypical Antipsychotics Through U.S. Outpatient Retail Pharmacies, Years 2004-2008 and YTD 2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %
<b>TOTAL MARKET</b>	<b>24,435,769</b>	<b>100.0%</b>	<b>25,290,095</b>	<b>100.0%</b>	<b>27,109,846</b>	<b>100.0%</b>	<b>29,707,935</b>	<b>100.0%</b>	<b>31,965,360</b>	<b>100.0%</b>	<b>16,343,519</b>	<b>100.0%</b>
<b>quetiapine fumarate</b>	7,172,254	29.4%	8,419,610	33.3%	9,566,459	35.3%	11,035,967	37.1%	11,872,722	37.1%	5,963,461	36.5%
Age 0-2	1,699	0.0%	1,703	0.0%	947	0.0%	1,046	0.0%	1,098	0.0%	798	0.0%
Age 3-6	36,137	0.5%	36,281	0.4%	32,513	0.3%	30,117	0.3%	24,597	0.2%	10,748	0.2%
Age 7-12	343,520	4.8%	377,005	4.5%	373,152	3.9%	383,639	3.5%	375,127	3.2%	171,650	2.9%
Age 13-17	536,651	7.5%	602,560	7.2%	610,243	6.4%	673,230	6.1%	680,203	5.7%	323,583	5.4%
Age 18+	6,054,350	84.4%	7,150,280	84.9%	8,425,490	88.1%	9,854,520	89.3%	10,711,958	90.2%	5,416,244	90.8%
Age UNSPEC.	199,897	2.8%	251,781	3.0%	124,114	1.3%	93,415	0.8%	79,739	0.7%	40,438	0.7%
<b>risperidone</b>	7,667,075	31.4%	7,450,347	29.5%	7,633,454	28.2%	7,842,904	26.4%	7,851,019	24.6%	3,909,921	23.9%
Age 0-2	3,124	0.0%	2,852	0.0%	1,752	0.0%	1,773	0.0%	1,732	0.0%	1,025	0.0%
Age 3-6	162,316	2.1%	161,961	2.2%	156,514	2.1%	176,373	2.2%	180,597	2.3%	95,250	2.4%
Age 7-12	924,830	12.1%	922,797	12.4%	920,618	12.1%	1,015,666	13.0%	1,082,913	13.8%	535,714	13.7%
Age 13-17	766,990	10.0%	744,794	10.0%	732,124	9.6%	774,769	9.9%	785,940	10.0%	385,875	9.9%
Age 18+	5,604,683	73.1%	5,390,319	72.3%	5,714,933	74.9%	5,796,085	73.9%	5,734,679	73.0%	2,862,552	73.2%
Age UNSPEC.	205,132	2.7%	227,624	3.1%	107,513	1.4%	78,238	1.0%	65,158	0.8%	29,505	0.8%
<b>aripiprazole</b>	2,217,551	9.1%	3,050,315	12.1%	3,690,981	13.6%	4,227,419	14.2%	5,220,564	16.3%	3,077,023	18.8%
Age 0-2	458	0.0%	429	0.0%	362	0.0%	475	0.0%	463	0.0%	258	0.0%
Age 3-6	21,827	1.0%	27,738	0.9%	31,990	0.9%	35,691	0.8%	37,238	0.7%	21,166	0.7%
Age 7-12	244,100	11.0%	336,863	11.0%	373,046	10.1%	403,937	9.6%	453,042	8.7%	244,630	8.0%
Age 13-17	336,590	15.2%	478,936	15.7%	556,357	15.1%	608,186	14.4%	693,438	13.3%	369,882	12.0%
Age 18+	1,551,509	70.0%	2,109,978	69.2%	2,672,209	72.4%	3,136,033	74.2%	3,994,310	76.5%	2,415,407	78.5%
Age UNSPEC.	63,067	2.8%	96,371	3.2%	57,017	1.5%	43,097	1.0%	42,073	0.8%	25,680	0.8%
<b>olanzapine</b>	6,025,933	24.7%	4,739,568	18.7%	4,258,848	15.7%	4,057,714	13.7%	4,047,558	12.7%	1,912,135	11.7%
Age 0-2	2,165	0.0%	1,414	0.0%	299	0.0%	311	0.0%	292	0.0%	98	0.0%
Age 3-6	21,237	0.4%	11,091	0.2%	7,096	0.2%	5,714	0.1%	5,796	0.1%	2,291	0.1%
Age 7-12	153,592	2.5%	99,708	2.1%	74,435	1.7%	66,974	1.7%	66,751	1.6%	30,087	1.6%
Age 13-17	208,910	3.5%	140,147	3.0%	110,137	2.6%	102,154	2.5%	96,282	2.4%	44,347	2.3%
Age 18+	5,478,380	90.9%	4,344,711	91.7%	4,017,648	94.3%	3,848,724	94.8%	3,850,788	95.1%	1,823,196	95.3%
Age UNSPEC.	161,649	2.7%	142,497	3.0%	49,233	1.2%	33,837	0.8%	27,649	0.7%	12,116	0.6%
<b>ziprasidone hcl</b>	1,352,956	5.5%	1,630,255	6.4%	1,960,104	7.2%	2,226,104	7.5%	2,318,478	7.3%	1,146,227	7.0%
Age 0-2	326	0.0%	268	0.0%	131	0.0%	155	0.0%	120	0.0%	71	0.0%
Age 3-6	3,613	0.3%	3,532	0.2%	3,540	0.2%	3,292	0.1%	2,268	0.1%	1,135	0.1%
Age 7-12	60,038	4.4%	69,035	4.2%	76,972	3.9%	81,291	3.7%	74,767	3.2%	36,085	3.1%
Age 13-17	113,057	8.4%	131,155	8.0%	148,365	7.6%	165,173	7.4%	161,270	7.0%	75,963	6.6%
Age 18+	1,135,815	84.0%	1,368,607	84.0%	1,703,176	86.9%	1,953,822	87.8%	2,061,278	88.9%	1,023,218	89.3%
Age UNSPEC.	40,107	3.0%	57,658	3.5%	27,920	1.4%	22,371	1.0%	18,775	0.8%	9,755	0.9%
<b>paliperidone</b>	--	--	--	--	--	--	317,827	1.1%	655,019	2.0%	334,752	2.0%
Age 0-2	--	--	--	--	--	--	11	0.0%	47	0.0%	44	0.0%
Age 3-6	--	--	--	--	--	--	669	0.2%	1,414	0.2%	739	0.2%
Age 7-12	--	--	--	--	--	--	11,576	3.6%	28,842	4.4%	14,911	4.5%
Age 13-17	--	--	--	--	--	--	20,401	6.4%	44,256	6.8%	23,474	7.0%
Age 18+	--	--	--	--	--	--	280,177	88.2%	572,274	87.4%	290,628	86.8%
Age UNSPEC.	--	--	--	--	--	--	4,993	1.6%	8,186	1.2%	4,956	1.5%

Source: SDI: Vector One®: National. Data Extracted 8-4-09. File: VONA 2009-1004 TRx by Age 8-4-09.qry

**Table 2. Total Number of Unique Patients Receiving a Prescription for Atypical Antipsychotics Through U.S. Outpatient Retail Pharmacies, 2004-2008 and YTD 2009**

	2004		2005		2006		2007		2008		YTD/Jun/2009	
	N	%	N	%	N	%	N	%	N	%	N	%
<b>Total Market</b>	<b>4,489,529</b>	<b>100.00%</b>	<b>4,444,417</b>	<b>100.00%</b>	<b>4,660,191</b>	<b>100.00%</b>	<b>4,969,311</b>	<b>100.00%</b>	<b>5,448,785</b>	<b>100.00%</b>	<b>3,979,597</b>	<b>100.00%</b>
<b>Seroquel (quetiapine)</b>	<b>1,542,314</b>	<b>34.35%</b>	<b>1,744,179</b>	<b>39.24%</b>	<b>1,943,537</b>	<b>41.71%</b>	<b>2,173,053</b>	<b>43.73%</b>	<b>2,328,813</b>	<b>42.74%</b>	<b>1,598,624</b>	<b>40.17%</b>
Age 0 - 2	733	0.05%	627	0.04%	468	0.02%	404	0.02%	404	0.02%	220	0.01%
Age 3 - 6	10,707	0.69%	10,796	0.62%	9,335	0.48%	8,181	0.38%	6,417	0.28%	3,235	0.20%
Age 7 - 12	77,174	5.00%	80,094	4.59%	74,182	3.82%	73,534	3.38%	69,600	2.99%	42,902	2.68%
Age 13 - 17	127,799	8.29%	136,274	7.81%	134,575	6.92%	143,089	6.58%	144,049	6.19%	87,255	5.46%
Age 18+	1,286,368	83.41%	1,468,844	84.21%	1,707,151	87.84%	1,938,939	89.23%	2,101,066	90.22%	1,443,541	90.30%
Age Unknown	101,492	6.58%	124,134	7.12%	76,081	3.91%	65,269	3.00%	59,756	2.57%	57,669	3.61%
<b>Risperdal (risperidone)</b>	<b>1,636,139</b>	<b>36.44%</b>	<b>1,509,737</b>	<b>33.97%</b>	<b>1,509,463</b>	<b>32.39%</b>	<b>1,494,606</b>	<b>30.08%</b>	<b>1,503,005</b>	<b>27.58%</b>	<b>1,042,096</b>	<b>26.19%</b>
Age 0 - 2	1,447	0.09%	1,134	0.08%	858	0.06%	839	0.06%	815	0.05%	459	0.04%
Age 3 - 6	42,650	2.61%	41,423	2.74%	39,736	2.63%	44,954	3.01%	44,826	2.98%	28,973	2.78%
Age 7 - 12	198,238	12.12%	188,643	12.50%	185,525	12.29%	199,999	13.38%	209,582	13.94%	142,276	13.65%
Age 13 - 17	179,153	10.95%	164,151	10.87%	158,286	10.49%	163,168	10.92%	166,088	11.05%	107,105	10.28%
Age 18+	1,188,123	72.62%	1,087,272	72.02%	1,125,055	74.53%	1,095,544	73.30%	1,093,219	72.74%	750,737	72.04%
Age Unknown	114,435	6.99%	117,445	7.78%	68,382	4.53%	54,187	3.63%	46,842	3.12%	38,831	3.73%
<b>Abilify (aripirazole)</b>	<b>575,962</b>	<b>12.83%</b>	<b>725,022</b>	<b>16.31%</b>	<b>825,454</b>	<b>17.71%</b>	<b>915,745</b>	<b>18.43%</b>	<b>1,208,577</b>	<b>22.18%</b>	<b>964,705</b>	<b>24.24%</b>
Age 0 - 2	233	0.04%	195	0.03%	175	0.02%	249	0.03%	241	0.02%	160	0.02%
Age 3 - 6	6,936	1.20%	8,483	1.17%	9,293	1.13%	10,091	1.10%	10,615	0.88%	7,109	0.74%
Age 7 - 12	60,650	10.53%	76,754	10.59%	82,490	9.99%	86,358	9.43%	98,721	8.17%	71,090	7.37%
Age 13 - 17	87,968	15.27%	114,087	15.74%	128,565	15.58%	137,757	15.04%	162,896	13.48%	114,121	11.83%
Age 18+	411,479	71.44%	514,202	70.92%	607,348	73.58%	689,179	75.26%	945,073	78.20%	764,989	79.30%
Age Unknown	30,721	5.33%	42,536	5.87%	27,288	3.31%	21,425	2.34%	20,105	1.66%	15,663	1.62%
<b>Zyprexa (olanzapine)</b>	<b>1,254,933</b>	<b>27.95%</b>	<b>908,070</b>	<b>20.43%</b>	<b>787,437</b>	<b>16.90%</b>	<b>726,628</b>	<b>14.62%</b>	<b>740,794</b>	<b>13.60%</b>	<b>481,685</b>	<b>12.10%</b>
Age 0 - 2	948	0.08%	448	0.05%	142	0.02%	160	0.02%	202	0.03%	57	0.01%
Age 3 - 6	6,489	0.52%	3,354	0.37%	2,283	0.29%	1,781	0.25%	1,690	0.23%	729	0.15%
Age 7 - 12	39,070	3.11%	23,312	2.57%	17,006	2.16%	14,824	2.04%	14,878	2.01%	8,571	1.78%
Age 13 - 17	56,719	4.52%	35,088	3.86%	26,246	3.33%	23,339	3.21%	22,677	3.06%	12,774	2.65%
Age 18+	1,117,925	89.08%	817,910	90.07%	732,619	93.04%	681,079	93.73%	696,535	94.03%	453,480	94.14%
Age Unknown	85,310	6.80%	71,869	7.91%	33,561	4.26%	25,209	3.47%	21,353	2.88%	17,939	3.72%
<b>Geodon (ziprasidone)</b>	<b>316,573</b>	<b>7.05%</b>	<b>351,282</b>	<b>7.90%</b>	<b>403,596</b>	<b>8.66%</b>	<b>432,926</b>	<b>8.71%</b>	<b>444,925</b>	<b>8.17%</b>	<b>295,929</b>	<b>7.44%</b>
Age 0 - 2	141	0.04%	67	0.02%	74	0.02%	71	0.02%	77	0.02%	49	0.02%
Age 3 - 6	1,289	0.41%	1,259	0.36%	1,029	0.25%	952	0.22%	692	0.16%	392	0.13%
Age 7 - 12	14,662	4.63%	15,757	4.49%	16,769	4.15%	16,714	3.86%	14,953	3.36%	9,508	3.21%
Age 13 - 17	28,864	9.12%	30,720	8.75%	34,065	8.44%	34,941	8.07%	33,911	7.62%	19,865	6.71%
Age 18+	263,556	83.25%	292,639	83.31%	348,844	86.43%	379,138	87.58%	394,743	88.72%	263,531	89.05%
Age Unknown	19,100	6.03%	23,874	6.80%	14,223	3.52%	10,495	2.42%	8,835	1.99%	5,699	1.93%
<b>Invega (paliperidone)</b>							<b>107,840</b>	<b>2.17%</b>	<b>164,715</b>	<b>3.02%</b>	<b>99,788</b>	<b>2.51%</b>
Age 0 - 2							11	0.01%	31	0.02%	25	0.03%
Age 3 - 6							266	0.25%	424	0.26%	267	0.27%
Age 7 - 12							3,755	3.48%	6,717	4.08%	4,218	4.23%
Age 13 - 17							7,040	6.53%	11,139	6.76%	7,130	7.15%
Age 18+							95,363	88.43%	145,222	88.17%	86,716	86.90%
Age Unknown							2,768	2.57%	4,504	2.73%	2,295	2.30%

Source: SDI: Total Patient Tracker. Data Extracted 8-5-09 and 8-6-09. Files: TPT 2009-1004 Abilify Patient Count by Age 8-5-09.xls, TPT 2009-1004 Abilify Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Geodon Patient Count by Age 8-5-09.xls, TPT 2009-1004 Geodon Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Invega Patient Count by Age 8-5-09.xls, TPT 2009-1004 Invega Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Risperdal Patient Count by Age 8-5-09.xls, TPT 2009-1004 Risperdal Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Seroquel Patient Count by Age 8-5-09.xls, TPT 2009-1004 Seroquel Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Total Patient Count 8-6-09.xls, TPT 2009-1004 Total Patient Count YTD 2009 8-6-09.xls, TPT 2009-1004 Zyprexa Patient Count by Age 8-5-09.xls, TPT 2009-1004 Zyprexa Patient Count by Age YTD 2009 8-5-09.xls

Table 3a. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009

	Uses (000)	Share (%)
<b>TOTAL MARKET</b>	<b>95,454</b>	<b>100.0%</b>
quetiapine fumarate	28,547	29.9%
<b>Age 3-6</b>	<b>45</b>	<b>0.2%</b>
2969 AFFECT PSYCHOSES NEC/NOS	4	
2967 BIPOLAR AFFECTIVE NOS	13	
3003 OBSESSIVE-COMPULSIVE DIS	5	
3129 CONDUCT DISTURBANCE NOS	7	
3123 IMPULSE CONTROL DIS NEC	7	
3139 EMOTIONAL DIS CHILD NOS	6	
2962 DEPR PSYCH, SINGL EPISOD	5	
<b>Age 7-12</b>	<b>365</b>	<b>1.3%</b>
3110 DEPRESSIVE DISORDER NEC	24	
3138 OTH EMOTIONAL DIS CHILD	22	
2968 MANIC-DEPRESSIVE NEC/NOS	5	
2998 EARLY CHLD PSYCHOSES NEC	12	
3000 ANXIETY STATES	6	
3129 CONDUCT DISTURBANCE NOS	19	
2967 BIPOLAR AFFECTIVE NOS	81	
3098 OTHER ADJUST REACTION	24	
3003 OBSESSIVE-COMPULSIVE DIS	10	
2969 AFFECT PSYCHOSES NEC/NOS	47	
All Others	116	
<b>Age 13-17</b>	<b>723</b>	<b>2.5%</b>
2969 AFFECT PSYCHOSES NEC/NOS	75	10.4%
2967 BIPOLAR AFFECTIVE NOS	147	20.3%
3140 ATTENTION DEFICIT DIS	34	4.7%
2968 MANIC-DEPRESSIVE NEC/NOS	26	3.6%
3098 OTHER ADJUST REACTION	28	3.9%
3123 IMPULSE CONTROL DIS NEC	42	5.8%
3138 OTH EMOTIONAL DIS CHILD	61	8.4%
3139 EMOTIONAL DIS CHILD NOS	5	0.7%
3120 UNSOCIALIZED AGGRESSION	5	0.7%
2959 SCHIZOPHRENIA NOS	16	2.2%
All Others	285	39.4%
<b>Age 18+</b>	<b>26,271</b>	<b>92.0%</b>
2967 BIPOLAR AFFECTIVE NOS	5,041	19.2%
2957 SCHIZOAFFECTIVE TYPE	2,298	8.7%
2968 MANIC-DEPRESSIVE NEC/NOS	1,063	4.0%
2953 PARANOID SCHIZOPHRENIA	1,399	5.3%
3110 DEPRESSIVE DISORDER NEC	1,497	5.7%
2959 SCHIZOPHRENIA NOS	1,491	5.7%
2989 PSYCHOSIS NOS	1,160	4.4%
3098 OTHER ADJUST REACTION	1,034	3.9%
2962 DEPR PSYCH, SINGL EPISOD	1,542	5.9%
2966 BIPOLAR AFFECTIVE, MIXED	919	3.5%
All Others	8,831	33.6%
<b>Age UNSPEC.</b>	<b>1,140</b>	<b>4.0%</b>

Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry

Table 3b. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009

	Uses (000)	Share (%)
<b>aripiprazole</b>	<b>16,449</b>	<b>17.2%</b>
<b>Age 0-2</b>	<b>21</b>	<b>0.1%</b>
3140 ATTENTION DEFICIT DIS	7	
V409 MENTAL/BEHAVIOR PROB NOS	7	
2956 RESIDUAL SCHIZOPHRENIA	8	
<b>Age 3-6</b>	<b>88</b>	<b>0.5%</b>
3072 TICS	3	
2968 MANIC-DEPRESSIVE NEC/NOS	5	
2967 BIPOLAR AFFECTIVE NOS	11	
3140 ATTENTION DEFICIT DIS	17	
3003 OBSESSIVE-COMPULSIVE DIS	7	
3009 NEUROTIC DISORDER NOS	5	
2999 EARLY CHLD PSYCHOSIS NOS	5	
7834 LACK NORM PHYSIOL DEVEL	4	
3138 OTH EMOTIONAL DIS CHILD	6	
3129 CONDUCT DISTURBANCE NOS	18	
All Others	7	
<b>Age 7-12</b>	<b>652</b>	<b>4.0%</b>
2969 AFFECT PSYCHOSES NEC/NOS	93	14.3%
3140 ATTENTION DEFICIT DIS	110	16.9%
2967 BIPOLAR AFFECTIVE NOS	163	25.0%
2990 INFANTILE AUTISM	34	5.2%
3138 OTH EMOTIONAL DIS CHILD	55	8.4%
2999 EARLY CHLD PSYCHOSIS NOS	7	1.1%
3003 OBSESSIVE-COMPULSIVE DIS	24	3.7%
3139 EMOTIONAL DIS CHILD NOS	6	0.9%
2998 EARLY CHLD PSYCHOSES NEC	12	1.8%
3129 CONDUCT DISTURBANCE NOS	43	6.6%
All Others	108	16.6%
<b>Age 13-17</b>	<b>1,331</b>	<b>8.1%</b>
2969 AFFECT PSYCHOSES NEC/NOS	109	8.2%
2967 BIPOLAR AFFECTIVE NOS	192	14.4%
3110 DEPRESSIVE DISORDER NEC	57	4.3%
3138 OTH EMOTIONAL DIS CHILD	178	13.4%
3140 ATTENTION DEFICIT DIS	137	10.3%
3129 CONDUCT DISTURBANCE NOS	58	4.4%
2962 DEPR PSYCH, SINGL EPISOD	62	4.7%
3000 ANXIETY STATES	11	0.8%
2968 MANIC-DEPRESSIVE NEC/NOS	22	1.7%
3098 OTHER ADJUST REACTION	53	4.0%
All Others	455	34.2%
<b>Age 18+</b>	<b>13,479</b>	<b>81.9%</b>
2967 BIPOLAR AFFECTIVE NOS	2,443	18.1%
2957 SCHIZOAFFECTIVE TYPE	1,518	11.3%
2968 MANIC-DEPRESSIVE NEC/NOS	825	6.1%
3110 DEPRESSIVE DISORDER NEC	553	4.1%
2959 SCHIZOPHRENIA NOS	1,275	9.5%
2962 DEPR PSYCH, SINGL EPISOD	722	5.4%
2953 PARANOID SCHIZOPHRENIA	1,329	9.9%
2989 PSYCHOSIS NOS	904	6.7%
2963 DEPR PSYCH, RECUR EPISOD	429	3.2%
2966 BIPOLAR AFFECTIVE, MIXED	434	3.2%
All Others	3,048	22.6%
<b>Age UNSPEC.</b>	<b>879</b>	<b>5.3%</b>

Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry

Table 3c. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009

	Uses (000)	Share (%)
<b>risperidone</b>	<b>22,080</b>	<b>23.1%</b>
<b>Age 0-2</b>	<b>19</b>	<b>0.1%</b>
3129 CONDUCT DISTURBANCE NOS	4	
V403 BEHAVIORAL PROBLEMS NEC	5	
V409 MENTAL/BEHAVIOR PROB NOS	6	
3138 OTH EMOTIONAL DIS CHILD	4	
<b>Age 3-6</b>	<b>405</b>	<b>1.8%</b>
3129 CONDUCT DISTURBANCE NOS	27	
3003 OBSESSIVE-COMPULSIVE DIS	16	
2967 BIPOLAR AFFECTIVE NOS	44	
3128 OTHER CONDUCT DISTURB	15	
2969 AFFECT PSYCHOSES NEC/NOS	51	
7803 CONVULSIONS	4	
3013 EXPLOSIVE PERSONALITY	4	
2990 INFANTILE AUTISM	32	
V403 BEHAVIORAL PROBLEMS NEC	11	
2989 PSYCHOSIS NOS	7	
All Others	193	
<b>Age 7-12</b>	<b>918</b>	<b>4.2%</b>
2990 INFANTILE AUTISM	102	11.1%
3140 ATTENTION DEFICIT DIS	164	17.9%
3138 OTH EMOTIONAL DIS CHILD	100	10.9%
2967 BIPOLAR AFFECTIVE NOS	136	14.8%
2969 AFFECT PSYCHOSES NEC/NOS	61	6.6%
2966 BIPOLAR AFFECTIVE, MIXED	6	0.7%
V403 BEHAVIORAL PROBLEMS NEC	26	2.8%
7805 SLEEP DISTURBANCES	12	1.3%
2989 PSYCHOSIS NOS	18	2.0%
3129 CONDUCT DISTURBANCE NOS	34	3.7%
All Others	255	27.8%
<b>Age 13-17</b>	<b>812</b>	<b>3.7%</b>
2969 AFFECT PSYCHOSES NEC/NOS	103	12.7%
2967 BIPOLAR AFFECTIVE NOS	102	12.6%
3072 TICS	38	4.7%
3110 DEPRESSIVE DISORDER NEC	34	4.2%
3140 ATTENTION DEFICIT DIS	127	15.6%
3138 OTH EMOTIONAL DIS CHILD	50	6.2%
2990 INFANTILE AUTISM	56	6.9%
3003 OBSESSIVE-COMPULSIVE DIS	17	2.1%
2953 PARANOID SCHIZOPHRENIA	15	1.8%
3190 MENTAL RETARDATION NOS	5	0.6%
All Others	266	32.8%
<b>Age 18+</b>	<b>19,122</b>	<b>86.6%</b>
2953 PARANOID SCHIZOPHRENIA	2,795	14.6%
2957 SCHIZOAFFECTIVE TYPE	2,176	11.4%
2959 SCHIZOPHRENIA NOS	1,758	9.2%
2967 BIPOLAR AFFECTIVE NOS	2,058	10.8%
2989 PSYCHOSIS NOS	1,412	7.4%
2948 OTH PERSIS MED DISO NOS	567	3.0%
3098 OTHER ADJUST REACTION	354	1.9%
2962 DEPR PSYCH, SINGL EPISOD	957	5.0%
3000 ANXIETY STATES	233	1.2%
2963 DEPR PSYCH, RECUR EPISOD	383	2.0%
All Others	6,427	33.6%
<b>Age UNSPEC.</b>	<b>806</b>	<b>3.7%</b>

Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry

**Table 3d. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009**

	Uses (000)	Share (%)
<b>olanzapine</b>	<b>16,362</b>	<b>17.1%</b>
<b>Age 3-6</b>	<b>33</b>	<b>0.2%</b>
2967 BIPOLAR AFFECTIVE NOS	6	
2962 DEPR PSYCH, SINGL EPISOD	5	
3110 DEPRESSIVE DISORDER NEC	5	
3098 OTHER ADJUST REACTION	6	
3140 ATTENTION DEFICIT DIS	4	
2960 MANIC DIS, SINGL EPISODE	7	
<b>Age 7-12</b>	<b>95</b>	<b>0.6%</b>
3140 ATTENTION DEFICIT DIS	15	
2990 INFANTILE AUTISM	11	
3000 ANXIETY STATES	6	
2969 AFFECT PSYCHOSES NEC/NOS	10	
2966 BIPOLAR AFFECTIVE, MIXED	11	
2959 SCHIZOPHRENIA NOS	6	
2998 EARLY CHLD PSYCHOSES NEC	11	
3098 OTHER ADJUST REACTION	5	
V202 ROUTIN CHILD HEALTH EXAM	6	
2960 MANIC DIS, SINGL EPISODE	14	
<b>Age 13-17</b>	<b>392</b>	<b>2.4%</b>
2967 BIPOLAR AFFECTIVE NOS	60	15.3%
3098 OTHER ADJUST REACTION	8	2.0%
2998 EARLY CHLD PSYCHOSES NEC	19	4.8%
2964 BIPOLAR AFFECTIVE, MANIC	15	3.8%
2989 PSYCHOSIS NOS	41	10.5%
3071 ANOREXIA NERVOSA	22	5.6%
2954 AC SCHIZOPHRENIC EPISODE	7	1.8%
3003 OBSESSIVE-COMPULSIVE DIS	12	3.1%
2953 PARANOID SCHIZOPHRENIA	14	3.6%
3110 DEPRESSIVE DISORDER NEC	29	7.4%
All Others	166	42.3%
<b>Age 18+</b>	<b>15,169</b>	<b>92.7%</b>
2959 SCHIZOPHRENIA NOS	1,898	12.5%
2957 SCHIZOAFFECTIVE TYPE	1,822	12.0%
2967 BIPOLAR AFFECTIVE NOS	2,224	14.7%
2953 PARANOID SCHIZOPHRENIA	1,902	12.5%
2989 PSYCHOSIS NOS	969	6.4%
3110 DEPRESSIVE DISORDER NEC	696	4.6%
2962 DEPR PSYCH, SINGL EPISOD	871	5.7%
2968 MANIC-DEPRESSIVE NEC/NOS	325	2.1%
2948 OTH PERSIS MED DISO NOS	210	1.4%
3098 OTHER ADJUST REACTION	230	1.5%
All Others	4,022	26.5%
<b>Age UNSPEC.</b>	<b>671</b>	<b>4.1%</b>

Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry

Table 3e. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009

	Uses (000)	Share (%)
<b>ziprasidone hcl</b>	<b>10,632</b>	<b>11.1%</b>
Age 0-2	8	0.1%
2956 RESIDUAL SCHIZOPHRENIA	8	
Age 3-6	7	0.1%
2957 SCHIZOAFFECTIVE TYPE	7	
Age 7-12	137	1.3%
2969 AFFECT PSYCHOSES NEC/NOS	17	
2967 BIPOLAR AFFECTIVE NOS	41	
3138 OTH EMOTIONAL DIS CHILD	14	
3003 OBSESSIVE-COMPULSIVE DIS	6	
4939 ASTHMA NOS	6	
3140 ATTENTION DEFICIT DIS	9	
2999 EARLY CHLD PSYCHOSIS NOS	14	
3000 ANXIETY STATES	5	
2966 BIPOLAR AFFECTIVE, MIXED	15	
3098 OTHER ADJUST REACTION	6	
All Others	5	
Age 13-17	234	2.2%
2967 BIPOLAR AFFECTIVE NOS	56	23.9%
3110 DEPRESSIVE DISORDER NEC	9	3.8%
7805 SLEEP DISTURBANCES	11	4.7%
2969 AFFECT PSYCHOSES NEC/NOS	21	9.0%
3138 OTH EMOTIONAL DIS CHILD	13	5.6%
2957 SCHIZOAFFECTIVE TYPE	12	5.1%
2948 OTH PERSIS MED DISO NOS	5	2.1%
V681 ISSUE REPEAT PRESCRIPT	5	2.1%
3123 IMPULSE CONTROL DIS NEC	5	2.1%
2989 PSYCHOSIS NOS	6	2.6%
All Others	90	38.5%
Age 18+	9,911	93.2%
2967 BIPOLAR AFFECTIVE NOS	1,598	16.1%
2953 PARANOID SCHIZOPHRENIA	1,666	16.8%
2957 SCHIZOAFFECTIVE TYPE	1,390	14.0%
2959 SCHIZOPHRENIA NOS	1,003	10.1%
2966 BIPOLAR AFFECTIVE, MIXED	490	4.9%
2968 MANIC-DEPRESSIVE NEC/NOS	486	4.9%
2989 PSYCHOSIS NOS	572	5.8%
2962 DEPR PSYCH, SINGL EPISOD	517	5.2%
2963 DEPR PSYCH, RECUR EPISOD	171	1.7%
3110 DEPRESSIVE DISORDER NEC	259	2.6%
All Others	1,760	17.8%
Age UNSPEC.	337	3.2%
<b>paliperidone</b>	<b>1,385</b>	<b>1.5%</b>
Age 7-12	7	0.5%
3129 CONDUCT DISTURBANCE NOS	7	
Age 13-17	32	2.3%
2957 SCHIZOAFFECTIVE TYPE	6	18.8%
3129 CONDUCT DISTURBANCE NOS	6	18.8%
V403 BEHAVIORAL PROBLEMS NEC	5	15.6%
2990 INFANTILE AUTISM	9	28.1%
2989 PSYCHOSIS NOS	7	21.9%
Age 18+	1,313	94.8%
2953 PARANOID SCHIZOPHRENIA	292	22.2%
2957 SCHIZOAFFECTIVE TYPE	206	15.7%
2959 SCHIZOPHRENIA NOS	168	12.8%
2967 BIPOLAR AFFECTIVE NOS	160	12.2%
2966 BIPOLAR AFFECTIVE, MIXED	42	3.2%
2962 DEPR PSYCH, SINGL EPISOD	95	7.2%
2968 MANIC-DEPRESSIVE NEC/NOS	90	6.9%
2964 BIPOLAR AFFECTIVE, MANIC	16	1.2%
2963 DEPR PSYCH, RECUR EPISOD	42	3.2%
2956 RESIDUAL SCHIZOPHRENIA	11	0.8%
All Others	193	14.7%
Age UNSPEC.	33	2.4%

Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry

Table 4a. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %
<b>TOTAL MARKET</b>	<b>24,071,730</b>	<b>100.00%</b>	<b>24,941,679</b>	<b>100.00%</b>	<b>26,764,745</b>	<b>100.00%</b>	<b>29,265,565</b>	<b>100.00%</b>	<b>28,149,646</b>	<b>100.00%</b>	<b>12,269,230</b>	<b>100.00%</b>
<b>Abilify (aripiprazole)</b>	2,217,546	9.21%	3,050,282	12.23%	3,691,019	13.79%	4,227,461	14.45%	5,220,570	18.55%	3,077,034	25.08%
<b>PSYCH</b>	1,436,130	64.76%	1,978,067	64.85%	2,518,219	68.23%	2,831,349	66.98%	3,509,474	67.22%	2,016,640	65.54%
Age 0-2	268	0.02%	220	0.01%	181	0.01%	185	0.01%	334	0.01%	177	0.01%
Age 3-6	17,463	1.22%	23,563	1.19%	26,816	1.06%	29,048	1.03%	32,872	0.94%	16,431	0.81%
Age 7-12	173,168	12.06%	240,499	12.16%	265,153	10.53%	281,379	9.94%	329,939	9.40%	173,695	8.61%
Age 13-17	225,853	15.73%	326,399	16.50%	382,649	15.20%	407,821	14.40%	483,751	13.78%	263,885	13.09%
Age 18+	1,019,378	70.98%	1,387,386	70.14%	1,843,419	73.20%	2,112,915	74.63%	2,662,578	75.87%	1,562,452	77.48%
<b>NP</b>	100,163	4.52%	158,707	5.20%	242,579	6.57%	316,849	7.50%	468,707	8.98%	304,514	9.90%
Age 0-2	11	0.01%	12	0.01%	19	0.01%	43	0.01%	28	0.01%	8	0.00%
Age 3-6	1,269	1.27%	2,033	1.28%	2,653	1.09%	3,124	0.99%	4,384	0.94%	2,565	0.84%
Age 7-12	11,280	11.26%	18,555	11.69%	24,617	10.15%	29,721	9.38%	37,876	8.08%	22,367	7.35%
Age 13-17	12,722	12.70%	21,734	13.69%	30,694	12.65%	38,392	12.12%	53,329	11.38%	31,097	10.21%
Age 18+	74,880	74.76%	116,374	73.33%	184,596	76.10%	245,570	77.50%	373,090	79.60%	248,477	81.60%
<b>UNSPEC</b>	432,004	19.48%	538,216	17.64%	400,687	10.86%	435,161	10.29%	365,909	7.01%	158,698	5.16%
Age 0-2	162	0.04%	109	0.02%	108	0.03%	177	0.04%	110	0.03%	64	0.04%
Age 3-6	6,201	1.44%	6,186	1.15%	6,739	1.68%	8,045	1.85%	5,136	1.40%	1,732	1.09%
Age 7-12	46,211	10.70%	53,884	10.01%	53,448	13.34%	58,144	13.36%	42,197	11.53%	16,183	10.20%
Age 13-17	54,602	12.64%	68,938	12.81%	70,242	17.53%	81,290	18.68%	61,240	16.74%	21,947	13.83%
Age 18+	324,828	75.19%	409,099	76.01%	270,150	67.42%	287,505	66.07%	257,227	70.30%	118,772	74.84%
<b>GP/FM/DO</b>	70,276	3.17%	113,576	3.72%	178,046	4.82%	226,512	5.36%	329,953	6.32%	247,728	8.05%
Age 0-2	19	0.03%	57	0.05%	32	0.02%	34	0.01%	44	0.01%	9	0.00%
Age 3-6	1,048	1.49%	1,152	1.01%	1,236	0.69%	1,608	0.71%	1,544	0.47%	1,145	0.46%
Age 7-12	5,852	8.33%	9,112	8.02%	11,664	6.55%	13,051	5.76%	16,128	4.89%	9,724	3.93%
Age 13-17	7,654	10.89%	12,640	11.13%	16,636	9.34%	21,116	9.32%	29,157	8.84%	17,004	6.86%
Age 18+	55,704	79.26%	90,616	79.78%	148,478	83.39%	190,703	84.19%	283,079	85.79%	219,846	88.74%
<b>IM</b>	33,118	1.49%	52,487	1.72%	78,680	2.13%	101,620	2.40%	146,588	2.81%	108,553	3.53%
Age 0-2	61	0.18%	6	0.01%	0	0.00%	69	0.07%	52	0.04%	2	0.00%
Age 3-6	91	0.27%	186	0.35%	114	0.15%	166	0.16%	244	0.17%	100	0.09%
Age 7-12	595	1.80%	1,053	2.01%	1,486	1.89%	1,472	1.45%	2,066	1.41%	889	0.82%
Age 13-17	1,360	4.11%	1,929	3.67%	2,878	3.66%	3,685	3.63%	4,541	3.10%	1,999	1.84%
Age 18+	31,012	93.64%	49,312	93.95%	74,203	94.31%	96,227	94.69%	139,686	95.29%	105,564	97.25%
<b>PED</b>	32,998	1.49%	52,379	1.72%	65,093	1.76%	74,253	1.76%	94,959	1.82%	55,225	1.79%
Age 0-2	21	0.06%	61	0.12%	33	0.05%	50	0.07%	56	0.06%	14	0.03%
Age 3-6	2,804	8.50%	4,017	7.67%	4,540	6.98%	5,503	7.41%	6,487	6.83%	3,758	6.81%
Age 7-12	14,226	43.11%	22,919	43.76%	27,095	41.62%	29,217	39.35%	36,875	38.83%	21,062	38.14%
Age 13-17	10,059	30.48%	16,169	30.87%	20,660	31.74%	24,644	33.19%	31,290	32.95%	18,071	32.72%
Age 18+	5,887	17.84%	9,213	17.59%	12,765	19.61%	14,839	19.99%	20,252	21.33%	12,320	22.31%
<b>All Others</b>	112,858	5.09%	156,850	5.15%	207,715	5.61%	241,717	5.70%	304,979	5.84%	185,675	6.04%

Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom\_Spec by Age\_HMehta081309.xls

Table 4b. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs	Share	TRxs	Share	TRxs	Share	TRxs	Share	TRxs	Share	TRxs	Share
	N	%	N	%	N	%	N	%	N	%	N	%
<b>Geodon (ziprasidone)</b>	1,352,910	5.62%	1,630,228	6.54%	1,960,134	7.32%	2,226,123	7.61%	2,318,585	8.24%	1,146,214	9.34%
<b>PSYCH</b>	855,485	63.23%	1,034,783	63.47%	1,339,002	68.31%	1,487,955	66.84%	1,572,081	67.80%	787,272	68.68%
Age 0-2	61	0.01%	70	0.01%	89	0.01%	118	0.01%	76	0.00%	43	0.01%
Age 3-6	3,274	0.38%	3,234	0.31%	2,966	0.22%	3,065	0.21%	2,190	0.14%	1,079	0.14%
Age 7-12	45,031	5.26%	54,342	5.25%	60,419	4.51%	63,964	4.30%	60,131	3.82%	28,371	3.60%
Age 13-17	78,620	9.19%	91,902	8.88%	108,328	8.09%	116,865	7.85%	117,357	7.47%	56,354	7.16%
Age 18+	728,498	85.16%	885,236	85.55%	1,167,200	87.17%	1,303,942	87.63%	1,392,328	88.57%	701,426	89.10%
<b>NP</b>	53,785	3.98%	73,942	4.54%	118,815	6.06%	159,700	7.17%	196,251	8.46%	108,965	9.51%
Age 0-2	64	0.12%	0	0.00%	2	0.00%	0	0.00%	8	0.00%	0	0.00%
Age 3-6	103	0.19%	227	0.31%	333	0.28%	352	0.22%	283	0.14%	116	0.11%
Age 7-12	2,053	3.82%	2,738	3.70%	3,718	3.13%	5,078	3.18%	6,060	3.09%	3,275	3.01%
Age 13-17	3,459	6.43%	4,706	6.36%	7,012	5.90%	10,194	6.38%	12,474	6.36%	6,125	5.62%
Age 18+	48,106	89.44%	66,271	89.63%	107,749	90.69%	144,076	90.22%	177,426	90.41%	99,450	91.27%
<b>GP/FM/DO</b>	63,712	4.71%	87,310	5.36%	126,913	6.47%	158,617	7.13%	166,510	7.18%	82,285	7.18%
Age 0-2	14	0.02%	30	0.03%	14	0.01%	2	0.00%	17	0.01%	6	0.01%
Age 3-6	165	0.26%	256	0.29%	199	0.16%	131	0.08%	263	0.16%	71	0.09%
Age 7-12	1,699	2.67%	2,193	2.51%	2,373	1.87%	2,576	1.62%	2,464	1.48%	1,289	1.57%
Age 13-17	3,227	5.06%	4,354	4.99%	5,635	4.44%	6,521	4.11%	6,529	3.92%	2,631	3.20%
Age 18+	58,608	91.99%	80,477	92.17%	118,690	93.52%	149,387	94.18%	157,237	94.43%	78,289	95.14%
<b>UNSPEC</b>	261,343	19.32%	291,451	17.88%	189,462	9.67%	199,570	8.96%	151,654	6.54%	56,015	4.89%
Age 0-2	69	0.03%	32	0.01%	26	0.01%	35	0.02%	35	0.02%	14	0.02%
Age 3-6	1,000	0.38%	952	0.33%	959	0.51%	776	0.39%	458	0.30%	86	0.15%
Age 7-12	12,103	4.63%	11,962	4.10%	11,209	5.92%	11,978	6.00%	8,131	5.36%	2,617	4.67%
Age 13-17	19,478	7.45%	20,090	6.89%	17,959	9.48%	20,882	10.46%	14,322	9.44%	4,797	8.56%
Age 18+	228,692	87.51%	258,415	88.67%	159,310	84.09%	165,899	83.13%	128,708	84.87%	48,501	86.59%
<b>IM</b>	33,086	2.45%	44,196	2.71%	59,256	3.02%	72,087	3.24%	76,090	3.28%	37,269	3.25%
Age 0-2	10	0.03%	0	0.00%	5	0.01%	2	0.00%	4	0.01%	0	0.00%
Age 3-6	59	0.18%	32	0.07%	24	0.04%	17	0.02%	3	0.00%	0	0.00%
Age 7-12	232	0.70%	164	0.37%	209	0.35%	223	0.31%	432	0.57%	134	0.36%
Age 13-17	528	1.60%	650	1.47%	632	1.07%	943	1.31%	1,139	1.50%	445	1.19%
Age 18+	32,257	97.49%	43,351	98.09%	58,385	98.53%	70,902	98.36%	74,513	97.93%	36,691	98.45%
<b>PA</b>	7,316	0.54%	9,518	0.58%	15,914	0.81%	24,068	1.08%	30,092	1.30%	16,169	1.41%
Age 0-2	0	0.00%	0	0.00%	2	0.01%	3	0.01%	0	0.00%	0	0.00%
Age 3-6	21	0.29%	22	0.23%	38	0.24%	51	0.21%	8	0.03%	3	0.02%
Age 7-12	107	1.46%	232	2.43%	380	2.39%	641	2.66%	580	1.93%	238	1.47%
Age 13-17	391	5.35%	413	4.34%	739	4.64%	1,146	4.76%	1,309	4.35%	1,127	6.97%
Age 18+	6,797	92.90%	8,852	93.00%	14,755	92.72%	22,228	92.35%	28,195	93.70%	14,800	91.54%
<b>All Others</b>	78,184	5.79%	89,027	5.44%	110,774	5.66%	124,126	5.54%	125,905	5.43%	58,239	5.07%

Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom\_Spec by Age\_HMhta081309.xls

Table 4c. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %
<b>Invega (paliperidone)</b>	0		0		0		317,806	1.09%	655,038	2.33%	334,731	2.73%
<b>PSYCH</b>	0		0		0		228,470	71.89%	469,875	71.73%	238,628	71.29%
Age 0-2	0		0		0		12	0.01%	40	0.01%	10	0.00%
Age 3-6	0		0		0		726	0.32%	1,391	0.30%	740	0.31%
Age 7-12	0		0		0		9,414	4.12%	22,719	4.84%	11,723	4.91%
Age 13-17	0		0		0		16,250	7.11%	34,800	7.41%	18,282	7.66%
Age 18+	0		0		0		202,067	88.44%	410,925	87.45%	207,874	87.11%
<b>NP</b>	0		0		0		28,824	9.07%	67,156	10.25%	38,289	11.44%
Age 0-2	0		0		0		0	0.00%	0	0.00%	20	0.05%
Age 3-6	0		0		0		56	0.19%	272	0.40%	62	0.16%
Age 7-12	0		0		0		904	3.14%	2,629	3.91%	1,376	3.59%
Age 13-17	0		0		0		1,117	3.88%	2,866	4.27%	1,958	5.11%
Age 18+	0		0		0		26,747	92.79%	61,390	91.41%	34,872	91.08%
<b>UNSPEC</b>	0		0		0		31,392	9.88%	46,366	7.08%	18,509	5.53%
Age 0-2	0		0		0		2	0.01%	0	0.00%	10	0.05%
Age 3-6	0		0		0		144	0.46%	258	0.56%	32	0.17%
Age 7-12	0		0		0		1,581	5.04%	2,412	5.20%	806	4.36%
Age 13-17	0		0		0		2,385	7.60%	3,568	7.69%	1,054	5.70%
Age 18+	0		0		0		27,280	86.90%	40,129	86.55%	16,607	89.72%
<b>GP/FM/DO</b>	0		0		0		9,311	2.93%	24,613	3.76%	13,890	4.15%
Age 0-2	0		0		0		0	0.00%	8	0.03%	0	0.00%
Age 3-6	0		0		0		49	0.52%	189	0.77%	25	0.18%
Age 7-12	0		0		0		261	2.81%	735	2.99%	456	3.28%
Age 13-17	0		0		0		488	5.24%	1,533	6.23%	855	6.16%
Age 18+	0		0		0		8,512	91.42%	22,149	89.99%	12,554	90.38%
<b>PA</b>	0		0		0		3,380	1.06%	9,184	1.40%	5,508	1.65%
Age 3-6	0		0		0		15	0.45%	7	0.08%	8	0.14%
Age 7-12	0		0		0		120	3.56%	315	3.43%	220	3.99%
Age 13-17	0		0		0		134	3.96%	356	3.88%	310	5.63%
Age 18+	0		0		0		3,111	92.04%	8,506	92.61%	4,970	90.24%
<b>IM</b>	0		0		0		3,937	1.24%	9,108	1.39%	5,025	1.50%
Age 3-6	0		0		0		1	0.03%	8	0.08%	3	0.05%
Age 7-12	0		0		0		54	1.38%	112	1.23%	65	1.30%
Age 13-17	0		0		0		63	1.60%	197	2.16%	104	2.07%
Age 18+	0		0		0		3,819	96.98%	8,792	96.53%	4,854	96.58%
<b>All Others</b>	0		0		0		12,491	3.91%	28,735	4.37%	14,882	4.45%

Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom\_Spec by Age\_HMehta081309.xls

Table 4d. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %
<b>Risperdal (risperidone)</b>	7,543,998	31.34%	7,301,470	29.27%	7,477,240	27.94%	7,654,194	26.15%	7,655,715	27.20%	3,823,816	31.17%
<b>PSYCH</b>	3,745,638	49.65%	3,632,826	49.75%	4,010,284	53.63%	4,096,761	53.52%	4,192,905	54.77%	2,114,274	55.29%
Age 0-2	1,220	0.03%	1,019	0.03%	832	0.02%	863	0.02%	821	0.02%	352	0.02%
Age 3-6	95,901	2.56%	94,940	2.61%	94,478	2.36%	102,678	2.51%	107,152	2.56%	51,218	2.42%
Age 7-12	522,445	13.95%	516,935	14.23%	516,977	12.89%	548,853	13.40%	601,085	14.34%	300,441	14.21%
Age 13-17	423,808	11.31%	410,864	11.31%	410,883	10.25%	421,547	10.29%	440,437	10.50%	225,452	10.66%
Age 18+	2,702,264	72.14%	2,609,068	71.82%	2,987,114	74.49%	3,022,819	73.79%	3,043,411	72.58%	1,536,813	72.69%
<b>GP/FM/DO</b>	757,457	10.04%	766,263	10.49%	880,820	11.78%	877,362	11.46%	878,130	11.47%	453,257	11.85%
Age 0-2	640	0.08%	432	0.06%	155	0.02%	129	0.01%	226	0.03%	59	0.01%
Age 3-6	6,280	0.83%	6,900	0.91%	6,936	0.79%	7,481	0.85%	9,424	1.07%	5,043	1.11%
Age 7-12	36,177	4.78%	39,148	5.11%	40,088	4.55%	43,599	4.97%	52,743	6.01%	26,956	5.95%
Age 13-17	34,099	4.50%	34,381	4.49%	35,218	4.00%	37,436	4.27%	42,968	4.89%	21,212	4.68%
Age 18+	680,262	89.81%	685,362	89.44%	798,423	90.65%	788,718	89.90%	772,769	88.00%	399,986	88.25%
<b>UNSPEC</b>	1,438,178	19.06%	1,295,682	17.75%	773,181	10.34%	751,548	9.82%	528,013	6.90%	196,160	5.13%
Age 0-2	757	0.05%	762	0.06%	559	0.07%	541	0.07%	485	0.09%	131	0.07%
Age 3-6	41,062	2.86%	34,135	2.63%	29,242	3.78%	31,294	4.16%	21,132	4.00%	7,253	3.70%
Age 7-12	177,784	12.36%	150,436	11.61%	126,906	16.41%	138,068	18.37%	90,449	17.13%	31,140	15.87%
Age 13-17	121,825	8.47%	111,730	8.62%	92,401	11.95%	98,209	13.07%	62,814	11.90%	21,786	11.11%
Age 18+	1,096,750	76.26%	998,619	77.07%	524,073	67.78%	483,436	64.33%	353,132	66.88%	135,876	69.27%
<b>IM</b>	528,169	7.00%	519,277	7.11%	555,827	7.43%	549,338	7.18%	535,767	7.00%	274,419	7.18%
Age 0-2	410	0.08%	432	0.08%	93	0.02%	85	0.02%	57	0.01%	31	0.01%
Age 3-6	1,318	0.25%	1,159	0.22%	836	0.15%	664	0.12%	935	0.17%	447	0.16%
Age 7-12	4,700	0.89%	4,924	0.95%	4,244	0.76%	4,493	0.82%	4,910	0.92%	2,717	0.99%
Age 13-17	5,074	0.96%	4,874	0.94%	5,344	0.96%	5,257	0.96%	5,355	1.00%	2,526	0.92%
Age 18+	516,667	97.82%	507,888	97.81%	545,310	98.11%	538,839	98.09%	524,508	97.90%	268,699	97.92%
<b>NP</b>	292,103	3.87%	314,513	4.31%	404,437	5.41%	471,194	6.16%	552,322	7.21%	295,381	7.72%
Age 0-2	57	0.02%	47	0.02%	105	0.03%	64	0.01%	122	0.02%	62	0.02%
Age 3-6	6,354	2.18%	7,050	2.24%	8,589	2.12%	10,359	2.20%	14,339	2.60%	7,398	2.50%
Age 7-12	33,008	11.30%	36,939	11.74%	43,265	10.70%	53,821	11.42%	66,890	12.11%	36,487	12.35%
Age 13-17	24,333	8.33%	27,357	8.70%	30,693	7.59%	36,946	7.84%	45,916	8.31%	25,012	8.47%
Age 18+	228,352	78.17%	243,120	77.30%	321,785	79.56%	370,004	78.52%	425,055	76.96%	226,423	76.65%
<b>PED</b>	194,940	2.58%	207,201	2.84%	224,462	3.00%	264,033	3.45%	312,675	4.08%	167,177	4.37%
Age 0-2	776	0.40%	742	0.36%	604	0.27%	952	0.36%	968	0.31%	455	0.27%
Age 3-6	30,667	15.73%	31,184	15.05%	32,103	14.30%	39,559	14.98%	45,480	14.55%	24,168	14.46%
Age 7-12	89,881	46.11%	98,656	47.61%	104,145	46.40%	123,238	46.68%	151,199	48.36%	81,368	48.67%
Age 13-17	41,955	21.52%	45,468	21.94%	50,505	22.50%	58,349	22.10%	68,141	21.79%	37,306	22.32%
Age 18+	31,662	16.24%	31,150	15.03%	37,104	16.53%	41,934	15.88%	46,888	15.00%	23,879	14.28%
<b>All Others</b>	587,511	7.82%	565,707	7.77%	628,230	8.40%	643,958	8.40%	655,901	8.67%	323,150	9.80%

Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom\_Spec by Age\_HMehta081309.xls and VONA Custom\_Spec by Age\_HMehta081709\_v2.xls

Table 4e. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %	TRxs N	Share %
<b>Seroquel (quetiapine)</b>	7,171,944	29.79%	8,419,587	33.76%	9,566,473	35.74%	10,990,641	37.55%	11,508,989	40.89%	5,594,278	45.60%
<b>PSYCH</b>	3,862,827	53.86%	4,383,235	52.06%	5,101,434	53.33%	5,670,356	51.59%	5,887,683	51.16%	2,817,752	50.37%
Age 0-2	711	0.02%	753	0.02%	539	0.01%	239	0.00%	343	0.01%	103	0.00%
Age 3-6	29,108	0.75%	31,621	0.72%	28,346	0.56%	26,064	0.46%	22,750	0.39%	9,327	0.33%
Age 7-12	241,068	6.24%	267,431	6.10%	266,786	5.23%	270,165	4.76%	270,146	4.59%	117,418	4.17%
Age 13-17	357,227	9.25%	403,724	9.21%	414,677	8.13%	453,376	8.00%	453,882	7.71%	206,155	7.32%
Age 18+	3,234,712	83.74%	3,679,706	83.95%	4,391,086	86.08%	4,920,513	86.78%	5,140,563	87.31%	2,484,749	88.18%
<b>GP/FM/DO</b>	580,122	8.09%	832,220	9.88%	1,199,732	12.54%	1,520,784	13.84%	1,698,914	14.76%	875,993	15.66%
Age 0-2	222	0.04%	247	0.03%	182	0.02%	150	0.01%	243	0.01%	69	0.01%
Age 3-6	1,559	0.27%	1,482	0.18%	1,790	0.15%	2,152	0.14%	1,430	0.08%	509	0.06%
Age 7-12	10,175	1.75%	13,334	1.60%	14,849	1.24%	15,666	1.03%	16,547	0.97%	7,630	0.87%
Age 13-17	20,211	3.48%	25,981	3.12%	30,849	2.57%	37,361	2.46%	39,287	2.31%	18,603	2.12%
Age 18+	547,954	94.46%	791,175	95.07%	1,152,063	96.03%	1,465,456	96.36%	1,641,408	96.62%	849,181	96.94%
<b>IM</b>	414,482	5.78%	572,114	6.80%	773,075	8.08%	950,728	8.65%	1,079,951	9.38%	556,380	9.95%
Age 0-2	227	0.05%	252	0.04%	67	0.01%	425	0.04%	93	0.01%	7	0.00%
Age 3-6	372	0.09%	390	0.07%	376	0.05%	171	0.02%	213	0.02%	72	0.01%
Age 7-12	1,250	0.30%	1,359	0.24%	1,832	0.24%	1,949	0.21%	1,926	0.18%	857	0.15%
Age 13-17	3,865	0.93%	4,330	0.76%	5,246	0.68%	6,202	0.65%	5,658	0.52%	2,671	0.48%
Age 18+	408,768	98.62%	565,782	98.89%	765,554	99.03%	941,981	99.08%	1,072,061	99.27%	552,773	99.35%
<b>NP</b>	349,514	4.87%	431,131	5.12%	576,978	6.03%	718,882	6.54%	873,533	7.59%	461,255	8.25%
Age 0-2	84	0.02%	36	0.01%	61	0.01%	41	0.01%	29	0.00%	24	0.01%
Age 3-6	1,898	0.54%	2,042	0.47%	2,134	0.37%	2,444	0.34%	1,891	0.22%	791	0.17%
Age 7-12	16,312	4.67%	18,235	4.23%	21,190	3.67%	23,623	3.29%	27,138	3.11%	12,521	2.71%
Age 13-17	22,881	6.55%	26,544	6.16%	32,120	5.57%	38,735	5.39%	45,511	5.21%	22,666	4.91%
Age 18+	308,339	88.22%	384,273	89.13%	521,473	90.38%	654,038	90.98%	798,963	91.46%	425,253	92.19%
<b>UNSPEC</b>	1,272,895	17.75%	1,358,612	16.14%	893,227	9.34%	950,896	8.65%	719,903	6.26%	272,799	4.88%
Age 0-2	291	0.02%	280	0.02%	150	0.02%	155	0.02%	172	0.02%	55	0.02%
Age 3-6	9,751	0.77%	8,927	0.66%	6,769	0.76%	6,181	0.65%	3,647	0.51%	937	0.34%
Age 7-12	71,454	5.61%	68,065	5.01%	56,836	6.36%	59,559	6.26%	37,405	5.20%	12,185	4.47%
Age 13-17	93,289	7.33%	97,548	7.18%	86,230	9.65%	94,123	9.90%	58,094	8.07%	19,467	7.14%
Age 18+	1,098,110	86.27%	1,183,792	87.13%	743,242	83.21%	790,878	83.17%	620,585	86.20%	240,154	88.03%
<b>NEURO</b>	213,039	2.97%	247,201	2.94%	273,774	2.86%	298,569	2.72%	309,517	2.69%	148,654	2.66%
Age 0-2	82	0.04%	75	0.03%	44	0.02%	27	0.01%	10	0.00%	8	0.01%
Age 3-6	1,634	0.77%	1,630	0.66%	1,794	0.66%	1,752	0.59%	1,182	0.38%	376	0.25%
Age 7-12	6,875	3.23%	8,277	3.35%	8,230	3.01%	7,360	2.47%	6,357	2.05%	2,778	1.87%
Age 13-17	6,714	3.15%	7,372	2.98%	7,841	2.86%	8,552	2.86%	9,540	3.08%	4,221	2.84%
Age 18+	197,734	92.82%	229,847	92.98%	255,865	93.46%	280,877	94.07%	292,428	94.48%	141,272	95.03%
<b>All Others</b>	479,067	6.67%	595,075	7.07%	748,254	7.82%	880,425	8.01%	939,489	8.14%	461,445	8.27%

Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom\_Spec by Age\_HMhta081309.xls

Table 4f. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009

	2004		2005		2006		2007		2008		YTD/JUN/2009	
	TRxs	Share	TRxs	Share	TRxs	Share	TRxs	Share	TRxs	Share	TRxs	Share
	N	%	N	%	N	%	N	%	N	%	N	%
<b>Zyprexa (olanzapine)</b>	5,785,332	24.03%	4,540,114	18.20%	4,069,878	15.21%	3,849,340	13.15%	3,812,972	13.55%	1,797,758	14.65%
<b>PSYCH</b>	2,639,533	45.62%	2,093,756	46.12%	2,108,751	51.81%	2,008,844	52.19%	2,070,195	54.29%	982,803	54.67%
Age 0-2	640	0.02%	274	0.01%	137	0.01%	125	0.01%	100	0.00%	13	0.00%
Age 3-6	12,427	0.47%	6,814	0.33%	4,896	0.23%	4,625	0.23%	4,496	0.22%	1,680	0.17%
Age 7-12	88,479	3.35%	60,599	2.89%	46,942	2.23%	40,774	2.03%	42,983	2.08%	19,741	2.01%
Age 13-17	118,584	4.49%	81,313	3.88%	66,363	3.15%	60,150	2.99%	59,640	2.88%	27,346	2.78%
Age 18+	2,419,404	91.66%	1,944,756	92.88%	1,990,413	94.39%	1,903,170	94.74%	1,962,976	94.82%	934,023	95.04%
<b>GP/FM/DO</b>	835,679	14.44%	653,008	14.38%	631,786	15.52%	583,703	15.16%	562,740	14.76%	263,523	14.66%
Age 0-2	487	0.06%	458	0.07%	35	0.01%	39	0.01%	35	0.01%	2	0.00%
Age 3-6	1,907	0.23%	1,087	0.17%	553	0.09%	255	0.04%	281	0.05%	112	0.04%
Age 7-12	9,241	1.11%	5,656	0.87%	3,906	0.62%	3,164	0.54%	3,326	0.59%	1,534	0.58%
Age 13-17	15,901	1.90%	10,342	1.58%	7,179	1.14%	6,647	1.14%	6,341	1.13%	2,899	1.10%
Age 18+	808,144	96.71%	635,465	97.31%	620,113	98.15%	573,597	98.27%	552,755	98.23%	258,977	98.27%
<b>IM</b>	553,055	9.56%	438,127	9.65%	398,665	9.80%	358,655	9.32%	343,806	9.02%	163,144	9.07%
Age 0-2	453	0.08%	243	0.06%	29	0.01%	23	0.01%	24	0.01%	4	0.00%
Age 3-6	770	0.14%	292	0.07%	58	0.01%	43	0.01%	23	0.01%	13	0.01%
Age 7-12	1,103	0.20%	785	0.18%	458	0.11%	354	0.10%	159	0.05%	52	0.03%
Age 13-17	2,333	0.42%	1,687	0.38%	1,243	0.31%	1,049	0.29%	790	0.23%	353	0.22%
Age 18+	548,396	99.16%	435,121	99.31%	396,876	99.55%	357,187	99.59%	342,810	99.71%	162,722	99.74%
<b>NP</b>	215,933	3.73%	186,723	4.11%	213,358	5.24%	237,484	6.17%	280,833	7.37%	146,701	8.16%
Age 0-2	14	0.01%	7	0.00%	1	0.00%	10	0.00%	0	0.00%	6	0.00%
Age 3-6	750	0.35%	612	0.33%	336	0.16%	348	0.15%	425	0.15%	211	0.14%
Age 7-12	5,198	2.41%	3,798	2.03%	3,361	1.58%	3,115	1.31%	3,710	1.32%	1,867	1.27%
Age 13-17	6,257	2.90%	5,090	2.73%	4,142	1.94%	4,580	1.93%	5,507	1.96%	2,906	1.98%
Age 18+	203,713	94.34%	177,217	94.91%	205,519	96.33%	229,431	96.61%	271,192	96.57%	141,711	96.60%
<b>UNSPEC</b>	1,066,537	18.44%	798,572	17.59%	362,522	8.91%	329,907	8.57%	229,412	6.02%	89,777	4.99%
Age 0-2	300	0.03%	197	0.02%	55	0.02%	48	0.01%	103	0.04%	42	0.05%
Age 3-6	4,660	0.44%	2,336	0.29%	1,251	0.35%	1,018	0.31%	558	0.24%	112	0.12%
Age 7-12	30,225	2.83%	16,227	2.03%	9,370	2.58%	9,125	2.77%	5,857	2.55%	2,260	2.52%
Age 13-17	34,426	3.23%	19,612	2.46%	14,199	3.92%	13,404	4.06%	7,722	3.37%	2,857	3.18%
Age 18+	996,926	93.47%	760,200	95.19%	337,647	93.14%	306,312	92.85%	215,172	93.79%	84,505	94.13%
<b>HOSP</b>	97,391	1.68%	73,963	1.63%	76,120	1.87%	64,695	1.68%	54,898	1.44%	18,078	1.01%
Age 0-2	62	0.06%	23	0.03%	19	0.03%	50	0.08%	17	0.03%	13	0.07%
Age 3-6	245	0.25%	305	0.41%	93	0.12%	103	0.16%	76	0.14%	30	0.17%
Age 7-12	1,381	1.42%	1,117	1.51%	926	1.22%	691	1.07%	587	1.07%	265	1.47%
Age 13-17	2,417	2.48%	1,584	2.14%	1,274	1.67%	1,136	1.76%	1,017	1.85%	316	1.75%
Age 18+	93,286	95.78%	70,934	95.90%	73,808	96.96%	62,714	96.94%	53,202	96.91%	17,453	96.54%
<b>All Others</b>	377,203	6.47%	295,963	6.50%	278,676	6.86%	266,052	6.88%	271,088	7.10%	133,733	7.46%

Source: SDI: Vector One®. National. Custom Run: File: Copy of VONA Custom\_Spec by Age\_HMhta081309.xls

**Table 5a. Total Number of Mentions for Atypical Antipsychotics used Concomitantly with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient Retail Pharmacies, Jan 2004 - June 2009**

	<b>Occur (000)</b>	<b>Share %</b>
<b>TOTAL MARKET</b>	<b>89,263</b>	<b>100.0%</b>
quetiapine fumarate	26,426	29.6%
<b>Age 3-6</b>	<b>46</b>	<b>0.2%</b>
Used Alone	25	53.9%
20200 SEIZURE DISORDERS	7	14.4%
64190 ANTIPSYCHOTICS OTH	6	12.2%
64340 ANTI-DEPRESSANTS SSRIS	5	11.5%
64500 ANALEPTICS	4	8.0%
<b>Age 7-12</b>	<b>359</b>	<b>1.4%</b>
Used Alone	127	35.5%
20200 SEIZURE DISORDERS	75	20.9%
64500 ANALEPTICS	71	19.8%
64330 NEW GENERTN ANTIDEPR	53	14.7%
64190 ANTIPSYCHOTICS OTH	44	12.3%
64340 ANTI-DEPRESSANTS SSRIS	38	10.6%
31450 CENTRAL ACT ALONE/COMB	33	9.1%
64310 ANTIDEP TRI/TETRA	12	3.4%
64400 ANTI-MANIA	6	1.8%
<b>Age 13-17</b>	<b>663</b>	<b>2.5%</b>
Used Alone	290	43.6%
20200 SEIZURE DISORDERS	172	25.9%
64340 ANTI-DEPRESSANTS SSRIS	157	23.6%
64190 ANTIPSYCHOTICS OTH	96	14.5%
64400 ANTI-MANIA	58	8.8%
31450 CENTRAL ACT ALONE/COMB	21	3.2%
64500 ANALEPTICS	14	2.2%
64330 NEW GENERTN ANTIDEPR	14	2.1%
64700 NEW GENRTN PSYCH OTR	13	1.9%
78800 MISC ETHICALS OTHER	9	1.4%
17210 ANTNAUS ANTIDOPA PHENO	7	1.1%
All Others	5	0.7%
<b>Age 18+</b>	<b>24,298</b>	<b>91.9%</b>
Used Alone	7,093	29.2%
20200 SEIZURE DISORDERS	6,891	28.4%
64340 ANTI-DEPRESSANTS SSRIS	6,051	24.9%
64190 ANTIPSYCHOTICS OTH	3,105	12.8%
64330 NEW GENERTN ANTIDEPR	2,798	11.5%
64350 ANTI-DEPRESSANTS SNRIS	1,990	8.2%
64400 ANTI-MANIA	1,698	7.0%
64610 BENZODIAZEPINES	1,275	5.2%
64310 ANTIDEP TRI/TETRA	1,027	4.2%
20400 ALZHEIMER'S DISEASE TH	846	3.5%
67290 NON-BARBITUATE, OTHER	760	3.1%
64690 ANTIANXIETY OTHER	584	2.4%
64110 PHENOTHIAZINE DERIV	315	1.3%
20119 ANTIPRKNSON OTHER	264	1.1%
All Others	1,047	4.3%
<b>Age UNSPEC.</b>	<b>1,060</b>	<b>4.0%</b>

Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry

**Table 5b. Total Number of Mentions for Atypical Antipsychotics used Concomitantly with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient Retail Pharmacies, Jan 2004 - June 2009**

	Occur (000)	Share %
<b>risperidone</b>	20,531	23.0%
<b>Age 0-2</b>	19	0.1%
Used Alone	19	100.0%
<b>Age 3-6</b>	348	1.7%
Used Alone	274	78.9%
64500 ANALEPTICS	80	22.9%
31450 CENTRAL ACT ALONE/COMB	28	8.0%
64340 ANTI-DEPRESSANTS SSRIS	26	7.3%
20200 SEIZURE DISORDERS	11	3.3%
All Others	3	0.8%
<b>Age 7-12</b>	827	4.0%
Used Alone	490	59.3%
64500 ANALEPTICS	201	24.3%
31450 CENTRAL ACT ALONE/COMB	104	12.5%
20200 SEIZURE DISORDERS	78	9.5%
64340 ANTI-DEPRESSANTS SSRIS	66	8.0%
64700 NEW GENRTN PSYCH OTR	45	5.5%
64190 ANTIPSYCHOTICS OTH	15	1.8%
64330 NEW GENERTN ANTIDEPR	14	1.7%
All Others	21	2.6%
<b>Age 13-17</b>	742	3.6%
Used Alone	381	51.3%
64500 ANALEPTICS	120	16.2%
64340 ANTI-DEPRESSANTS SSRIS	102	13.7%
20200 SEIZURE DISORDERS	92	12.4%
64330 NEW GENERTN ANTIDEPR	60	8.1%
31450 CENTRAL ACT ALONE/COMB	43	5.9%
64400 ANTI-MANIA	42	5.7%
64700 NEW GENRTN PSYCH OTR	31	4.2%
64190 ANTIPSYCHOTICS OTH	11	1.5%
64690 ANTIANXIETY OTHER	9	1.2%
64610 BENZODIAZEPINES	9	1.2%
All Others	24	3.2%
<b>Age 18+</b>	17,830	86.8%
Used Alone	6,339	35.6%
64340 ANTI-DEPRESSANTS SSRIS	4,036	22.6%
20200 SEIZURE DISORDERS	3,945	22.1%
64190 ANTIPSYCHOTICS OTH	1,934	10.8%
64330 NEW GENERTN ANTIDEPR	1,340	7.5%
64350 ANTI-DEPRESSANTS SNRIS	1,150	6.4%
64400 ANTI-MANIA	1,040	5.8%
20119 ANTIPRKNSON OTHER	893	5.0%
20400 ALZHEIMER'S DISEASE TH	806	4.5%
64610 BENZODIAZEPINES	782	4.4%
64310 ANTIDEP TRI/TETRA	568	3.2%
67290 NON-BARBITUATE, OTHER	342	1.9%
64690 ANTIANXIETY OTHER	305	1.7%
14110 ANTIHISTAMINE CAP-TAB	240	1.3%
All Others	625	3.5%
<b>Age UNSPEC.</b>	766	3.7%

Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry

**Table 5c. Total Number of Mentions for Atypical Antipsychotics used Concomitantly with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient Retail Pharmacies, Jan 2004 - June 2009**

	Occur (000)	Share %
<b>aripiprazole</b>	<b>15,506</b>	<b>17.4%</b>
<b>Age 0-2</b>	<b>14</b>	<b>0.1%</b>
Used Alone	13	93.3%
64190 ANTIPSYCHOTICS OTH	8	53.3%
<b>Age 3-6</b>	<b>76</b>	<b>0.5%</b>
Used Alone	73	95.7%
64500 ANALEPTICS	6	7.7%
64190 ANTIPSYCHOTICS OTH	6	7.3%
64340 ANTI-DEPRESSANTS SSRIS	3	3.3%
<b>Age 7-12</b>	<b>626</b>	<b>4.0%</b>
Used Alone	321	51.3%
64500 ANALEPTICS	140	22.3%
64190 ANTIPSYCHOTICS OTH	73	11.7%
31450 CENTRAL ACT ALONE/COMB	71	11.4%
20200 SEIZURE DISORDERS	53	8.5%
64340 ANTI-DEPRESSANTS SSRIS	50	7.9%
64700 NEW GENRTN PSYCH OTR	28	4.5%
64400 ANTI-MANIA	24	3.8%
64330 NEW GENERTN ANTIDEPR	17	2.7%
64310 ANTIDEP TRI/TETRA	12	1.9%
20119 ANTIPRKNSON OTHER	6	1.0%
All Others	6	0.9%
<b>Age 13-17</b>	<b>1,266</b>	<b>8.2%</b>
Used Alone	664	52.4%
64340 ANTI-DEPRESSANTS SSRIS	238	18.8%
64500 ANALEPTICS	156	12.3%
20200 SEIZURE DISORDERS	133	10.5%
64190 ANTIPSYCHOTICS OTH	125	9.9%
64330 NEW GENERTN ANTIDEPR	66	5.2%
64400 ANTI-MANIA	34	2.7%
64690 ANTIANXIETY OTHER	23	1.8%
64700 NEW GENRTN PSYCH OTR	23	1.8%
20119 ANTIPRKNSON OTHER	19	1.5%
31450 CENTRAL ACT ALONE/COMB	14	1.1%
All Others	53	4.2%
<b>Age 18+</b>	<b>12,673</b>	<b>81.7%</b>
Used Alone	3,687	29.1%
20200 SEIZURE DISORDERS	3,619	28.6%
64340 ANTI-DEPRESSANTS SSRIS	3,082	24.3%
64190 ANTIPSYCHOTICS OTH	1,858	14.7%
64330 NEW GENERTN ANTIDEPR	1,522	12.0%
64350 ANTI-DEPRESSANTS SNRIS	1,165	9.2%
64400 ANTI-MANIA	775	6.1%
64610 BENZODIAZEPINES	765	6.0%
64310 ANTIDEP TRI/TETRA	456	3.6%
67290 NON-BARBITUATE, OTHER	440	3.5%
64110 PHENOTHIAZINE DERIV	241	1.9%
76140 MULTIVIT GEN	227	1.8%
20119 ANTIPRKNSON OTHER	224	1.8%
64500 ANALEPTICS	176	1.4%
64690 ANTIANXIETY OTHER	157	1.2%
All Others	334	2.6%
<b>Age UNSPEC.</b>	<b>850</b>	<b>5.5%</b>

Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry

**Table 5d. Total Number of Mentions for Atypical Antipsychotics used Concomitantly with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient Retail Pharmacies, Jan 2004 - June 2009**

	<b>Occur (000)</b>	<b>Share %</b>
<b>olanzapine</b>	<b>15,314</b>	<b>17.2%</b>
<b>Age 3-6</b>	<b>34</b>	<b>0.2%</b>
Used Alone	6	17.1%
20200 SEIZURE DISORDERS	13	39.1%
64340 ANTI-DEPRESSANTS SSRIS	10	30.8%
64400 ANTI-MANIA	7	20.5%
64500 ANALEPTICS	4	13.0%
31450 CENTRAL ACT ALONE/COMB	4	13.0%
<b>Age 7-12</b>	<b>89</b>	<b>0.6%</b>
Used Alone	49	55.1%
31450 CENTRAL ACT ALONE/COMB	26	29.4%
64500 ANALEPTICS	23	25.7%
20200 SEIZURE DISORDERS	5	5.9%
64190 ANTIPSYCHOTICS OTH	5	5.8%
64340 ANTI-DEPRESSANTS SSRIS	4	4.3%
64330 NEW GENERTN ANTIDEPR	3	3.9%
<b>Age 13-17</b>	<b>329</b>	<b>2.2%</b>
Used Alone	153	46.5%
64340 ANTI-DEPRESSANTS SSRIS	85	25.7%
20200 SEIZURE DISORDERS	48	14.7%
64190 ANTIPSYCHOTICS OTH	40	12.1%
64400 ANTI-MANIA	22	6.7%
20119 ANTIPRKNSON OTHER	20	6.1%
64350 ANTI-DEPRESSANTS SNRIS	17	5.2%
64610 BENZODIAZEPINES	12	3.7%
67290 NON-BARBITUATE, OTHER	7	2.1%
64330 NEW GENERTN ANTIDEPR	7	2.1%
64310 ANTIDEP TRI/TETRA	6	1.9%
<b>Age 18+</b>	<b>14,226</b>	<b>92.9%</b>
Used Alone	5,598	39.3%
64340 ANTI-DEPRESSANTS SSRIS	3,432	24.1%
20200 SEIZURE DISORDERS	3,133	22.0%
64190 ANTIPSYCHOTICS OTH	1,263	8.9%
64330 NEW GENERTN ANTIDEPR	1,103	7.8%
64350 ANTI-DEPRESSANTS SNRIS	864	6.1%
64400 ANTI-MANIA	749	5.3%
64310 ANTIDEP TRI/TETRA	604	4.2%
64610 BENZODIAZEPINES	582	4.1%
64690 ANTIANXIETY OTHER	323	2.3%
20400 ALZHEIMER'S DISEASE TH	279	2.0%
64110 PHENOTHIAZINE DERIV	261	1.8%
67290 NON-BARBITUATE, OTHER	236	1.7%
20119 ANTIPRKNSON OTHER	176	1.2%
All Others	507	3.6%
<b>Age UNSPEC.</b>	<b>635</b>	<b>4.1%</b>

Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry

**Table 5e. Total Number of Mentions for Atypical Antipsychotics used Concomitantly with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient Retail Pharmacies, Jan 2004 - June 2009**

	<b>Occur (000)</b>	<b>Share %</b>
<b>ziprasidone hcl</b>	<b>10,154</b>	<b>11.4%</b>
<b>Age 0-2</b>	<b>8</b>	<b>0.1%</b>
64190 ANTIPSYCHOTICS OTH	8	100.0%
<b>Age 3-6</b>	<b>7</b>	<b>0.1%</b>
Used Alone	7	100.0%
<b>Age 7-12</b>	<b>118</b>	<b>1.2%</b>
Used Alone	48	40.5%
20200 SEIZURE DISORDERS	52	43.7%
64340 ANTI-DEPRESSANTS SSRIS	23	19.3%
64190 ANTIPSYCHOTICS OTH	20	16.6%
64400 ANTI-MANIA	12	10.0%
64330 NEW GENERTN ANTIDEPR	12	10.0%
20119 ANTIPRKNSON OTHER	7	5.7%
<b>Age 13-17</b>	<b>207</b>	<b>2.0%</b>
Used Alone	97	47.1%
64340 ANTI-DEPRESSANTS SSRIS	35	17.1%
64310 ANTIDEP TRI/TETRA	23	11.2%
64500 ANALEPTICS	21	10.1%
64190 ANTIPSYCHOTICS OTH	20	9.7%
31450 CENTRAL ACT ALONE/COMB	18	8.5%
20200 SEIZURE DISORDERS	13	6.4%
67210 SED NON-BARB CHLOR	12	5.8%
64610 BENZODIAZEPINES	12	5.8%
64690 ANTIANXIETY OTHER	6	2.9%
20119 ANTIPRKNSON OTHER	5	2.6%
<b>Age 18+</b>	<b>9,501</b>	<b>93.6%</b>
Used Alone	2,831	29.8%
20200 SEIZURE DISORDERS	2,659	28.0%
64340 ANTI-DEPRESSANTS SSRIS	1,989	20.9%
64190 ANTIPSYCHOTICS OTH	1,261	13.3%
64330 NEW GENERTN ANTIDEPR	902	9.5%
64400 ANTI-MANIA	756	8.0%
64350 ANTI-DEPRESSANTS SNRIS	722	7.6%
64610 BENZODIAZEPINES	480	5.1%
67290 NON-BARBITUATE, OTHER	321	3.4%
64310 ANTIDEP TRI/TETRA	303	3.2%
64110 PHENOTHIAZINE DERIV	260	2.7%
76140 MULTIVIT GEN	204	2.1%
20119 ANTIPRKNSON OTHER	164	1.7%
64690 ANTIANXIETY OTHER	137	1.4%
20400 ALZHEIMER'S DISEASE TH	118	1.2%
All Others	368	3.9%
<b>Age UNSPEC.</b>	<b>314</b>	<b>3.1%</b>
<b>paliperidone</b>	<b>1,333</b>	<b>1.5%</b>
<b>Age 7-12</b>	<b>7</b>	<b>0.5%</b>
Used Alone	7	100.0%
<b>Age 13-17</b>	<b>26</b>	<b>2.0%</b>
Used Alone	6	20.9%
64190 ANTIPSYCHOTICS OTH	18	68.9%
20200 SEIZURE DISORDERS	16	59.2%
64330 NEW GENERTN ANTIDEPR	6	20.9%
64690 ANTIANXIETY OTHER	5	19.9%
<b>Age 18+</b>	<b>1,266</b>	<b>95.0%</b>
Used Alone	452	35.7%
20200 SEIZURE DISORDERS	307	24.3%
64340 ANTI-DEPRESSANTS SSRIS	264	20.9%
64190 ANTIPSYCHOTICS OTH	157	12.4%
64350 ANTI-DEPRESSANTS SNRIS	145	11.5%
64400 ANTI-MANIA	117	9.2%
64330 NEW GENERTN ANTIDEPR	59	4.6%
64610 BENZODIAZEPINES	59	4.6%
67290 NON-BARBITUATE, OTHER	51	4.0%
20119 ANTIPRKNSON OTHER	24	1.9%
76140 MULTIVIT GEN	23	1.8%
64500 ANALEPTICS	23	1.8%
64110 PHENOTHIAZINE DERIV	19	1.5%
All Others	32	2.5%
<b>Age UNSPEC.</b>	<b>33</b>	<b>2.5%</b>

Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry

## **Appendix 2: Database Descriptions**

### ***SDI Vector One®: National (VONA)***

SDI's VONA measures retail dispensing of prescriptions or the frequency with which drugs move out of retail pharmacies into the hands of consumers via formal prescriptions. Information on the physician specialty, the patient's age and gender, and estimates for the numbers of patients that are continuing or new to therapy are available.

The Vector One® database integrates prescription activity from a variety of sources including national retail chains, mass merchandisers, mail order pharmacies, pharmacy benefits managers and their data systems, and provider groups. Vector One® receives over 2.0 billion prescription claims per year, representing over 160 million unique patients. Since 2002 Vector One® has captured information on over 8 billion prescriptions representing 200 million unique patients.

Prescriptions are captured from a sample of approximately 59,000 pharmacies throughout the US. The pharmacies in the data base account for nearly all retail pharmacies and represent nearly half of retail prescriptions dispensed nationwide. SDI receives all prescriptions from approximately one-third of the stores and a significant sample of prescriptions from the remaining stores.

### ***SDI Vector One®: Total Patient Tracker (TPT)***

SDI's Total Patient Tracker is a national-level projected audit designed to estimate the total number of unique patients across all drugs and therapeutic classes in the retail outpatient setting.

TPT derives its data from the Vector One® database which integrates prescription activity from a variety of sources including national retail chains, mail order pharmacies, mass merchandisers, pharmacy benefits managers and their data systems. Vector One® receives over 2 billion prescription claims per year, which represents over 160 million patients tracked across time.

### ***IMS Health, IMS National Sales Perspectives™: Retail and Non-Retail***

The IMS Health, IMS National Sales Perspectives™ measures the volume of drug products, both prescription and over-the-counter, and selected diagnostic products moving from manufacturers into various outlets within the retail and non-retail markets. Volume is expressed in terms of sales dollars, eaches, extended units, and share of market. These data are based on national projections. Outlets within the retail market include the following pharmacy settings: chain drug stores, independent drug stores, mass merchandisers, food stores, and mail service. Outlets within the non-retail market include clinics, non-federal hospitals, federal facilities, HMOs, long-term care facilities, home health care, and other miscellaneous settings.

### ***SDI Physician Drug & Diagnosis Audit (PDDA)***

SDI's Physician Drug & Diagnosis Audit (PDDA) is a monthly survey designed to provide descriptive information on the patterns and treatment of diseases encountered in office-based physician practices in the U.S. The survey consists of data collected from approximately 3,100 office-based physicians representing 29 specialties across the United States that report on all patient activity during one typical workday per month. These data may include profiles and trends of diagnoses, patients, drug products mentioned during the office visit and treatment patterns. The data are then projected nationally by physician specialty and region to reflect national prescribing patterns.

SDI uses the term "drug uses" to refer to mentions of a drug in association with a diagnosis during an office-based patient visit. This term may be duplicated by the number of diagnosis for which the drug is mentioned. It is important to note that a "drug use" does not necessarily result in prescription being generated. Rather, the term indicates that a given drug was mentioned during an office visit.

SDI uses the term "drug occurrences" to refer to the number of times a product has been reported on a patient information form during an office-based patient visit for that period. It is important to note that a "drug occurrence" does not necessarily result in a prescription being generated. A "drug occurrence" can result from a prescription written, a sample given, a recommendation for OTC products, recommendation with sample, a product dispensed or administered in the office, a hospital order, a nursing home order or a combination of these.

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

HINA S MEHTA  
09/10/2009

LAURA A GOVERNALE  
09/10/2009  
Cleared by data vendors for PAC background package.